On Tuesday, shares in Pennsylvania headquartered Egalet Corp. recorded a trading volume of 714,426 shares, which was above their three months average volume of 536,280 shares. The stock ended at $7.72, dropping 5.04% from the last trading session. The Company's shares have gained 1.58% in the last one month and 5.03% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 8.17% and 15.15%, respectively. Furthermore, shares of Egalet, which develops, manufactures, and commercializes treatments for patients with pain and other conditions, have a Relative Strength Index (RSI) of 52.02.
On December 06th, 2016, Egalet announced that the US Patent and Trademark Office has issued patent number 9,498,446 covering Egalet's proprietary Guardian™ Technology abuse-deterrent products which contain a matrix and an exterior shell including Phase 3 product candidate, Egalet-002. The patent offers protection through February 2030 for Egalet-002 and other products developed with a shell using Guardian Technology. EGLT complete research report is just a click away at:
New York headquartered TG Therapeutics Inc.'s stock finished yesterday's session 1.98% lower at $4.95, with a total trading volume of 370,462 shares. The Company's shares are trading below their 50-day moving average by 19.38%. Shares of TG Therapeutics, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the US, have an RSI of 33.25.
On December 06th, 2016, TG Therapeutics announced that the target enrollment of 120 patients in the GENUINE Phase 3 study has been met and enrollment will be closed shortly. The GENUINE Phase 3 study is a randomized study of TG-1101, the Company's novel, glycoengineered anti-CD20 monoclonal antibody in combination with ibrutinib, the oral Bruton's tyrosine kinase, versus ibrutinib alone in approximately 120 patients with high-risk relapsed or refractory Chronic Lymphocytic Leukemia. In October, the study was modified to convert the primary endpoint solely to Overall Response Rate. If the study results are positive, and subject to a positive outcome of pre-BLA meeting with the FDA, the Company plans to utilize the results to file for accelerated approval. The Company expects to release top-line data from the GENUINE Phase 3 study in H1 2017. The complimentary report on TGTX can be downloaded at:
At the closing bell on Tuesday, shares in Bermuda-based Axovant Sciences Ltd saw a decline of 3.96%, ending the day at $13.10, with a total trading volume of 243,278 shares. The stock is trading 1.67% below its 50-day moving average. Shares of the Company, which engages in acquiring, developing, and commercializing novel therapeutics for the treatment of dementia in the US and Europe, have an RSI of 43.67.
On December 07th, 2016, research firm Oppenheimer initiated an 'Outperform' rating on the Company's stock, issuing a target price of $20 per share.
On December 09th, 2016, Axovant Sciences announced a new analysis of the data from a Phase 2b trial evaluating treatment with intepirdine (RVT-101), combined with standard of care donepezil, and compared to donepezil plus placebo in people with mild-to-moderate Alzheimer's disease. The company stated that the analysis indicates that the addition of intepirdine to treatment was associated with reduced progression in dependence, suggesting that those in the study who received combination treatment spent more time in the earlier, less dependent stages of the disease. Sign up for your complimentary report on AXON at:
Pennsylvania headquartered Spark Therapeutics Inc.'s stock ended the day 0.89% lower at $52.17, with a total trading volume of 257,042 shares. The Company's shares have gained 15.14% on an YTD basis. The stock is trading 5.71% above its 200-day moving average. Additionally, shares of Spark Therapeutics, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases, have an RSI of 46.44.
As per a SEC filing dated December 08th, 2016, Spark Therapeutics entered into a License and Option Agreement with Selecta Biosciences, Inc. on December 2nd, 2016, that provides the Company with exclusive worldwide rights to Selecta's proprietary Synthetic Vaccine Particles platform technology for co-administration with gene therapy targets. The Company paid Selecta an upfront payment of $10 million and has agreed to make additional payments of an aggregate of $5.0 million within 12 months of the Signing Date. Download the research report for free on ONCE at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA